---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-065482"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2023-11-21T23:59:59+00:00"
generated_at: "2026-06-07T22:35:24.420091+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sutro Biopharma promotes Jane Chung to President and COO effective Dec 1, 2023

## Summary
- Jane Chung, previously Chief Commercial Officer, appointed President and COO, a newly created role.
- New compensation includes $560k base salary, up to 50% bonus, 35k stock options, and 100k RSUs.
- Chung previously served as President/GM of AstraZeneca Canada and VP of Immuno-Oncology at AstraZeneca.
- Role focuses on operational excellence, strategic growth, and cross-functional alignment across R&D and portfolio.

## SEC filing metadata
- accession: 0000950170-23-065482
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2023-11-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017023065482/0000950170-23-065482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017023065482/stro-20231121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-065482
- JSON: https://secwatch.observer/filing/0000950170-23-065482.json
- Plain text: https://secwatch.observer/filing/0000950170-23-065482.txt

## Key facts
- Executive change
  Jane Chung was appointed as President and Chief Operating Officer at SUTRO BIOPHARMA, INC..
  - Action: appointed
  - Role: President and Chief Operating Officer
  source text: On November 21, 2023, Sutro Biopharma, Inc. (the “Company”) announced the appointment of Jane Chung, currently the Company’s Chief Commercial Officer since August 2021, to the position of President and Chief Operating Officer of the Company, effective as of December 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000095017023065482/0000950170-23-065482-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.